Search from website
Search from website
Salipro Biotech and Icosagen announce the initiation of a multi-target collaboration for the discovery and characterization of monoclonal antibodies against several GPCRs and SLC transporters.
Stockholm, Sweden and Tartu, Estonia, October 10, 2023 – Swedish biotech company Salipro Biotech AB and Estonian biotechnology company Icosagen today announced that they entered into a multi-target antibody research agreement to advance drug discovery programs against several challenging membrane proteins, including G protein-coupled receptors (GPCRs) and solute carrier (SLC) transporters.
The partnership between Salipro Biotech and Icosagen will build on Salipro's track record of establishing multiple collaboration and licensing agreements with leading pharma and biotech companies to enable drug discovery against complex membrane protein targets, ranging from small molecule drug discovery programs to structural biology and antibody discovery.
“Our Salipro® technology provides an enabling platform for the discovery of therapeutics against challenging drug targets. We are excited to unlock the potential of these targets with Icosagen and develop novel drugs that can improve patient outcomes," said Jens Frauenfeld, CEO of Salipro Biotech.
Icosagen brings significant expertise in protein production and analytics to the partnership. Their knowledge in antibody discovery, encompassing high-throughput antibody screening and variety of lead optimization techniques will enrich the collaboration and form solid basis for supporting biologic drug developments in the future.
Mart Ustav Jr., CSO of Icosagen, said, "We are delighted to apply our QMCF technology and protein analytics capabilities in this project. Both teams in Icosagen and Salipro Biotech are always finding ways to push the boundaries in novel technologies of biologics development. It will be interesting to see what we’ll be able to achieve as we put our heads together for this project.”
About Icosagen
Icosagen, headquartered in Tartu, Estonia, and established in 1999, has evolved into a prominent biotechnology company with a dedicated team of over 190 experts. Icosagen is a unique Contract Research, Development, and Manufacturing Organization (CRDMO) that is a trusted ally for biotechnology and pharmaceutical companies seeking to advance the discovery and production of recombinant proteins and antibodies. The integration of CRO and CDMO capabilities empowers to deliver top-tier services throughout the complete journey of discovering, developing, and manufacturing mammalian protein drug candidates.
About Salipro Biotech AB
Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins.
To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs.
Press contacts:
Icosagen
Mart Ustav Jr.
CSO
+372 7377 084
Mart.ustav.jr@icosagen.com
https://www.icosagen.com
LinkedIn: https://www.linkedin.com/company/icosagen
Salipro Biotech AB
Jens Frauenfeld
CEO
+46 (0)700520421
jens.frauenfeld@salipro.com
For more information, please visit: https://www.salipro.com
LinkedIn: https://www.linkedin.com/company/salipro-biotech
Twitter: https://twitter.com/saliprobiotech
© 2024 Icosagen
